Qubit Pharmaceuticals

Qubit Pharmaceuticals is a pioneering deep-tech biotechnology company that integrates quantum physics, artificial intelligence, and high-performance computing to revolutionize the drug discovery process. By shifting the industry paradigm from traditional 'drug hunting' to a more precise 'drug farming' approach, the company utilizes its proprietary ATLAS platform to create digital twins of molecular interactions. This allows for the atom-by-atom design of drug candidates, significantly enhancing the efficacy and safety profiles of potential treatments for oncology, chronic inflammatory diseases, and pandemic-related threats. Founded in 2020 as a spin-off from decades of academic research, the company is led by a team of world-renowned scientists and experienced leadership. Qubit Pharmaceuticals leverages a hybrid computational infrastructure that combines polarizable force fields with massive supercomputing power to solve complex molecular problems. Recognized as a 2024 World Economic Forum Technology Pioneer, the company continues to bridge the gap between theoretical quantum chemistry and practical pharmaceutical development, aiming to drastically reduce the time and cost associated with bringing life-changing therapies to market.

Qubit Pharmaceuticals aims to bring unparalleled accuracy and precision to drug discovery and design, leveraging cutting-edge quantum sciences and AI to unlock new therapeutic possibilities and develop safer, more effective treatments for major diseases.

• Selected as a 2024 Technology Pioneer by the World Economic Forum
• Winner of the i-Lab and i-Nov innovation competitions
• Recipient of the Atos Joseph Fourier Prize
• Supported by the European Innovation Council (EIC) accelerator program
• Proprietary ATLAS platform capable of 50+ PetaFLOPS of computing power

Sources

• Official Qubit Pharmaceuticals Website
• World Economic Forum Technology Pioneer Announcement